...mOS). Study was powered to detect a significant difference with 80% probability at a significance level of 0,05 when 392...
...mos (range 5-13) after completion. All but four received from 1-5 prior treatment regimens, and 8 patients received prio...
...mos; 2 had received post-HDC radiation. 8 patients are alive and disease free 8 to 70 mos after completion of HDC (media...
...mos (median: 25 mos) after transpl, and 7 pts (14%) are alive at time of analysis, 7-75 mos (median: 40 mos) after trans...
...mos.), and one was successfully salvaged with McM with rituximab (McM+R) (NED at 51 months). One pt. treated with EPOCH+...
...mos and 3.7 mos in pts with SD. In pts treated with 400 mg imatinib there were no significant differences in PKs (t 22.0...
...mos (0.25+-9.6), median overall survival is 5.5+ mos (0.6-10.9+) (7 pts ongoing).,Combination of Cetuximab plus CAPOX ha...
...mos, when biopsies were repeated.,18 patients are evaluable at 3 mos, 10 at 12 mos. One patient was withdrawn for gr 2 a...
...mos (1-13.5 mos) with a 6-month progression-free probability rate of 43%. This difference in median TTP was highly signi...
...mos on adding 80 mg/M of Irinotecan to a 'failed' q2 wk Gemzar-Fluorouracil-Cisplatin regimen (The Oncologist 6:488 2001...
山东省济南市章丘区文博路2号
齐鲁师范学院 genelibs生信实验室
山东省济南市高新区舜华路750号
大学科技园北区F座4单元2楼
电话: 0531-88819269